NCT03618108 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Falk E, Shah PK, Fuster V
Coronary plaque disruption. Circulation. 1995 Aug 1;92(3):657-71. Review.
Hermus L, Lefrandt JD, Tio RA, Breek JC, Zeebregts CJ
Carotid plaque formation and serum biomarkers. Atherosclerosis. 2010 Nov;213(1):21-9. doi: 10.1016/j.atherosclerosis.2010.05.013. Epub 2010 May 19. Review. Erratum in: Atherosclerosis. 2011 May;216(1):249.

Phase IIa Prospective Study to Evaluate the Safety and Measure Efficacy of Anti-chlamydophila Antibiotic Combination (ACAC) Therapy Comprising 100mg Doxycycline, 500mg Azithromycin and 300mg Rifabutin in the Treatment of Patients With Coronary Heart Disease (CHD)

Details for clinical trial NCT03618108

Clinical trial NCT03618108 - References